-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
MoonLake Immunotherapeutics quarterly/annual Operating Income (Loss) history and growth rate from Q3 2020 to Q3 2024.
- MoonLake Immunotherapeutics Operating Income (Loss) for the quarter ending September 30, 2024 was -$43.1M, a 232% decline year-over-year.
- MoonLake Immunotherapeutics Operating Income (Loss) for the twelve months ending September 30, 2024 was -$109M, a 94.5% decline year-over-year.
- MoonLake Immunotherapeutics annual Operating Income (Loss) for 2023 was -$54.1M, a 16.8% increase from 2022.
- MoonLake Immunotherapeutics annual Operating Income (Loss) for 2022 was -$65.1M, a 1324% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)